radiation to tumors News
-
Theragenics to provide Sales and Marketing for C4 Imaging`s New Orion HDR MRI Markers
Theragenics Corporation, a medical device company serving the cancer treatment market, will provide sales and marketing for C4 Imaging’s novel, Orion Positive-Signal HDR MRI Lumen Marker. The marker is used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers, ...
-
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear detonation. “TP508 represents a natural product released at sites of tissue injury to ...
-
Clips. First We Pleaded for Them. Now, Not So Much: A Radiation Oncologist’s Perspective
It’s always been distressing to explain to surgeons that their meticulously placed lumpectomy clips are much less useful to radiation oncologists than they originally perceived. Maybe it’s because of the desperate appreciation that radiation oncologists express when even one clip is left behind. In this current era of de-escalating therapies, patients receiving breast radiation ...
-
Novel Tumor Bed Marking In Breast Cancer: Expanding Beyond Lumpectomy
VeraForm® placement to assist with localization and delivery of adjuvant radiation Historically, lumpectomies resulted in a scar immediately over the lumpectomy site, dictating delivery of adjuvant radiation on scar location, and frequently on the presence of a seroma. Currently, the question persists as to the optimal means to help direct the radiation oncologist to effectively deliver ...
-
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts
Diffusion Pharmaceuticals Inc.(NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced a significant expansion of its Scientific Advisory Board (SAB) to include five prominent radiation and medical oncologists to help guide ...
By CervoMed
-
Edinburgh Molecular Imaging Closes Financing
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...
-
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
-
First Simulated Patient Treatment Carried Out in the First Hospital-Based BNCT Facility in Europe
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
-
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
-
ABK Biomedical Inc. Raises $30M USD in Series B Financing
ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems. ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres™, which are designed for ...
-
GammaTile Therapy Delivers Targeted Radiation to Cancer Cells
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. The current standard of care for patients with ...
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam System for High-Precision Boron Neutron Capture Therapy
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with BEC GmbH (BEC) to incorporate a customized, robotic patient positioning system as part of its Alphabeam™ Neutron System for the high-precision radiation treatment of tumors. During BNCT, it is essential that the ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
GT Medical Technologies Wins Prestigious Innovator of the Year Award at the 2021 Governor`s Celebration of Innovation
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted ...
-
Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy
Ackerman Cancer Center (ACC), the world’s first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient. The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018. “Congratulations to the ...
-
Study Demonstrate Superiority of VeraForm® Marker Over Clips
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO conference in Chicago and the American College of ...
-
GT Medical Technologies Presents Clinical Data on GammaTile® Therapy for Brain Tumors at the 2021 American Association of Neurological Surgeons Scientific Virtual Meeting
GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company's breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The presenting authors, Dr. David Brachman, co-founder and CTO at GT Medical Technologies and Dr. Mehee Choi, director ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you